CE: Safely and Effectively Managing Excessive Daytime Sleepiness in Patients With Narcolepsy and Sleep Apnea

Pharmacy Times, August 2020, Volume 88, Issue 8

This activity is supported by an educational grant from Jazz Pharmaceuticals.

This activity is supported by an educational grant from Jazz Pharmaceuticals.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Describe the incidence, etiology, and risk factors associated with excessive daytime sleepiness (EDS) in those with narcolepsy and obstructive sleep apnea (OSA)
  • Identify the recommended treatments for EDS associated with narcolepsy and OSA, including pharmacologic and nonpharmacologic options
  • Evaluate clinical safety and efficacy data for emerging therapies, including mechanisms of action and potential adverse effects
  • Explain the role of the pharmacist in identifying and treating EDS in those with narcolepsy and OSA

FACULTY

John M. Dopp, PharmD, MS

Associate Professor, School of Pharmacy

Clinical Pharmacist, Wisconsin Sleep Center

University of Wisconsin-Madison, Madison, Wisconsin

TARGET AUDIENCE: Community pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: September 16, 2019

EXPIRATION DATE: September 16, 2020

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.